PCOS Acne: The Jawline Pattern, the Hormone Behind It, and What Clears It

How common is PCOS acne, and where does it actually show up

Acne affects 43% of women with PCOS compared with 21% of women without it — a 1.6-fold difference confirmed across 60 studies and more than 2 million women (Ramezani Tehrani et al., 2021). A more recent meta-analysis put the pooled prevalence even higher before adjusting for publication bias — 49%, revised to 37% once that adjustment was made — with regional rates ranging from 32% in Europe to 76% in Oceania (Pourahmad et al., 2025). That same analysis found acne was most common in patients under 18, next most common between 18 and 30, and least common past 30 — a pattern that tracks with cumulative years of treatment and androgen exposure more than any simple decline in the underlying cause.

Distribution is the first tell. PCOS-driven acne concentrates along the jawline, chin, lower cheeks and neck — the zone with the highest density of androgen-sensitive sebaceous glands — rather than the forehead and nose typical of teenage breakouts.

PCOS acne vs regular acne — what’s actually different

Four features separate the two patterns, and distribution is only the most visible one.

The persistence gap is the one people underestimate most. Teenage acne is driven by puberty’s hormonal surge, which by definition settles down as puberty ends — that’s why most people expect acne to be a phase. PCOS-driven acne doesn’t have that built-in expiry date, because the driver is ongoing androgen production, not a passing developmental stage, which is exactly why it shows up new, or worsens, well into someone’s 20s and 30s instead of following the teenage script.

What makes PCOS acne cystic

Excess androgen does two things to a follicle at once — it raises sebum output and speeds up skin-cell turnover inside the pore — and that combination is exactly what produces a plugged, deeply inflamed cyst instead of a surface pimple. Dihydrotestosterone, the more potent skin metabolite of testosterone, binds receptors that are especially dense on the jaw and lower face, which is the same reason that’s where both the acne and PCOS-related hirsutism concentrate.

Skin doesn’t just receive circulating androgens passively, either. Sebaceous glands and hair follicles carry their own 5-alpha-reductase enzyme, which converts testosterone into dihydrotestosterone locally, at concentrations the follicle actually experiences — independent of what a blood draw shows. That’s part of why acne severity doesn’t track perfectly with a serum testosterone number: someone with a normal lab result can still have highly androgen-responsive skin, and someone with a clearly elevated result can have relatively mild acne if their skin’s local conversion and receptor density happen to be lower. What a given lab result actually means is a separate question from whether the skin itself is reacting to it.

True nodulocystic acne is where oral isotretinoin earns its strong recommendation: the current dermatology guideline recommends it specifically for acne that is severe, causing psychosocial burden, causing scarring, or failing standard oral or topical therapy first (Reynolds et al., 2024). A well-established conventional course runs 0.5 to 1.0 mg/kg daily for 16 to 32 weeks, to a cumulative dose of 120 mg/kg. In a head-to-head trial comparing that standard dosing against a lower-dose and an intermittent regimen over roughly six months, both daily-dosing groups held up far better at one-year follow-up than the intermittent, pulsed schedule — 2 of 16 and 3 of 17 patients relapsed on the daily regimens, against 9 of 16 on the intermittent one (Lee et al., 2011). A separate high-dose trial found 97.4% of patients reported improvement at 12 months, with 32.7% relapsing by then regardless (Blasiak et al., 2013) — a fair warning that isotretinoin clears active lesions well but doesn’t switch off the underlying androgen signal driving them. Isotretinoin also comes with its own guideline-mandated monitoring — monthly pregnancy tests for anyone who can conceive, plus periodic liver and lipid checks — which is part of why it’s reserved for cases that need it rather than offered as a default first option.

In darker skin tones, inflamed lesions along the jaw are more likely to leave post-inflammatory hyperpigmentation than a scar in the traditional sense — a mark that typically fades over months rather than years, but that responds poorly to picking or aggressive extraction in the meantime. Treating the acne itself, early, does more for the mark it leaves behind than any product aimed at the discoloration alone.

Chest and back acne — same driver, different terrain

The sebaceous glands across the chest and upper back are just as androgen-sensitive as the ones on the jaw, which is why truncal acne so often shows up alongside facial acne in the same hormonal pattern rather than as a separate problem. The practical difference is coverage: a topical retinoid or benzoyl peroxide is realistic to apply consistently across a small facial area, much less so across an entire back, which is one reason oral options — a combined pill, spironolactone, or isotretinoin for severe cases — tend to do more for truncal acne than topicals alone. Loose, breathable fabric and showering soon after sweating help at the margins, but they don’t touch the androgen signal itself.

Truncal acne is also, practically, the most under-treated version of this pattern. It’s covered by clothing most of the day, it comes up less often in a dermatology visit that starts with the face, and it’s easy to assume it will resolve alongside facial acne when the two don’t always move in lockstep. Backpack straps, tight athletic wear and prolonged sweat contact can aggravate lesions that are already there through friction, but none of that is the underlying cause — treating the friction without treating the androgen driver behind it won’t clear a truncal breakout on its own.

What triggers a flare-up

Acne breakouts cluster in the week before a period for many women with hormonal acne, when a relative dip in estrogen unmasks androgen’s effect on the follicle more than usual. Blood sugar spikes are a second trigger worth tracking: higher circulating insulin pushes the ovaries to produce more androgen and increases sebum output directly, so a flare that tracks with a run of high-glycemic meals isn’t a coincidence — it’s the same insulin-androgen mechanism driving PCOS more broadly. Stress raises cortisol, which can push androgen output up indirectly, and switching to a progestin-only contraceptive is a known trigger in some women because it lacks the SHBG-raising effect of a combined pill.

Treatment options, ranked by how they work and how long they take

The pill’s case rests on a Cochrane review of 31 trials and more than 12,500 women, where every placebo-controlled comparison showed a combined pill reduced lesion counts, severity grades and self-assessed acne (Arowojolu et al., 2012). Spironolactone’s case is newer but consistent: a 2025 meta-analysis of five placebo-controlled trials found sixfold higher odds of objective improvement with spironolactone than with placebo, without a significant increase in menstrual irregularities or breast tenderness (Ghanem et al., 2025). What else spironolactone treats, and the potassium check it requires, is covered separately.

Does PCOS acne ever go away on its own?

Not reliably, and not the way teenage acne often does. Because the driver is ongoing androgen production rather than puberty’s temporary surge, PCOS-driven acne doesn’t have the same built-in expiry date — some women do see gradual improvement into their late 30s and 40s as androgen output naturally eases with age, but “waiting it out” for years carries the real cost of untreated cystic lesions: scarring in lighter skin, and persistent hyperpigmentation in darker skin, that treatment earlier would have prevented. Treating the acne is what changes the timeline; time alone rarely is.

Who this won’t help, or won’t help fast

A cleanser change or a stronger scrub does nothing for jawline or cystic acne, because the driver is androgen signaling inside the follicle, not surface oil — that’s the single biggest reason topical-only routines fail here specifically. Anti-androgens and combined pills are off the table during pregnancy or without reliable contraception, for the same feminisation-risk reason they’re restricted everywhere else in PCOS treatment. And isotretinoin, while the fastest option for severe cystic acne, carries its own monitoring requirements and isn’t a first pick for mild-to-moderate breakouts the guideline expects topicals to handle. If testosterone itself needs addressing rather than just the skin it’s affecting, that’s a longer, separate timeline — confirmed first against an actual lab range, not a symptom alone.

One more honest note: PCOS was renamed polyendocrine metabolic ovarian syndrome, or PMOS, in May 2026, by a global consensus of more than 50 organisations (Teede et al., 2026). The acne mechanism and every treatment above are unchanged — only the name on the diagnosis is different. This article uses PCOS, since that’s still what most readers search.

Your next step

Track where breakouts sit relative to your cycle for one full month before you change your routine — that single pattern tells you and a clinician whether you’re dealing with a flare that estrogen and progesterone are driving, or acne that needs an androgen-targeted treatment addressed on its own terms.